<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475837</url>
  </required_header>
  <id_info>
    <org_study_id>33763</org_study_id>
    <nct_id>NCT02475837</nct_id>
  </id_info>
  <brief_title>Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access</brief_title>
  <official_title>A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Mell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objectives of this study are:

        1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional
           maturation when administered during the maturation process compared with placebo.

        2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary
           procedures to aid in fistula maturation compared with placebo.

        3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for
           hemodialysis compared with placebo.

      This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be
      conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will
      be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health
      Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The
      investigators expect to enroll 128 patients. Patients will be assigned to treatment groups
      with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation.
      Patients will be stratified based on fistula location (lower arm versus upper arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional
           maturation when administered during the maturation process compared with placebo.

        2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary
           procedures to aid in fistula maturation compared with placebo.

        3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for
           hemodialysis compared with placebo.

      This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be
      conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will
      be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health
      Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The
      investigators expect to enroll 128 patients. Patients will be assigned to treatment groups
      with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation.
      Patients will be stratified based on fistula location (lower arm versus upper arm).

      Participation in this study will not affect standard care of patients with AV fistulae
      receiving hemodialysis. The only additional treatment is administration of the study drug or
      placebo and additional monitoring, including one additional ultrasound, for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2015</start_date>
  <completion_date type="Actual">December 5, 2017</completion_date>
  <primary_completion_date type="Actual">December 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to AV fistula functional maturation</measure>
    <time_frame>180 days</time_frame>
    <description>Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AV fistula use</measure>
    <time_frame>180 days</time_frame>
    <description>AV fistula use within 180 days of surgery.
AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AV fistula patency</measure>
    <time_frame>150-180 days</time_frame>
    <description>AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcomes - Bleeding events (GUSTO and BARC Criteria)</measure>
    <time_frame>180 days</time_frame>
    <description>Bleeding events (GUSTO and BARC Criteria)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Fistula Function Maturation</condition>
  <arm_group>
    <arm_group_label>Vorapaxar intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive the study drug: Vorapaxar sulfate.
The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive the matching placebo.
The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar sulfate</intervention_name>
    <description>The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.</description>
    <arm_group_label>Vorapaxar intervention</arm_group_label>
    <other_name>Zontivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.</description>
    <arm_group_label>Placebo intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18

          2. Receiving or planning to receive maintenance hemodialysis

          3. Ability to sign informed consent

          4. 3 mm venous diameter within recipient vein

        Exclusion Criteria:

          1. History of stroke, transient ischemic attack or intracranial hemorrhage

          2. History of or high level of suspicion for, severe arterial insufficiency of the hand

          3. Indication or ongoing therapy with other antiplatelet agents, other than aspirin 81 mg
             daily

          4. Indication or ongoing therapy with anticoagulants, including warfarin, low molecular
             weight heparin, factor Xa inhibitors or direct thrombin and other inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew W Mell, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Univeristy</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med. 1966 Nov 17;275(20):1089-92.</citation>
    <PMID>5923023</PMID>
  </reference>
  <reference>
    <citation>Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, Möhring K. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr. 1974 Apr 1;52(7):348-9.</citation>
    <PMID>4600820</PMID>
  </reference>
  <reference>
    <citation>Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002 Sep;13(9):2331-7.</citation>
    <PMID>12191977</PMID>
  </reference>
  <reference>
    <citation>Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs. 1985 Feb;9(1):61-3.</citation>
    <PMID>3888153</PMID>
  </reference>
  <reference>
    <citation>Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002786. doi: 10.1002/14651858.CD002786.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD002786.</citation>
    <PMID>18843633</PMID>
  </reference>
  <reference>
    <citation>Kaufman JS. Antithrombotic agents and the prevention of access thrombosis. Semin Dial. 2000 Jan-Feb;13(1):40-6. Review.</citation>
    <PMID>10740671</PMID>
  </reference>
  <reference>
    <citation>Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kusek JW, Lawson JH, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials. 2005;2(5):413-22.</citation>
    <PMID>16317810</PMID>
  </reference>
  <reference>
    <citation>Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):27-36. Epub 2006 Nov 9. Review.</citation>
    <PMID>17095716</PMID>
  </reference>
  <reference>
    <citation>Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.</citation>
    <PMID>22443427</PMID>
  </reference>
  <reference>
    <citation>Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.</citation>
    <PMID>22077816</PMID>
  </reference>
  <reference>
    <citation>Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.</citation>
    <PMID>22315147</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Matthew Mell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

